EBIT: Income before interest and taxes.
Rapt Therapeutics (RAPT) had EBIT of $-19.27M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-17.16M |
|
-- |
|
-- |
|
$19.27M |
|
$-19.27M |
|
$2.10M |
|
$-17.16M |
|
$-17.16M |
|
$-17.16M |
|
$-17.16M |
|
$-17.16M |
|
$-17.16M |
|
|
EBIT |
$-19.27M |
$-19.71M |
|
215.41M |
|
215.41M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$183.20M |
|
$1.16M |
|
$4.37M |
|
$187.57M |
|
$8.68M |
|
-- |
|
$1.52M |
|
$10.20M |
|
$177.37M |
|
$177.37M |
|
$177.37M |
|
132.01M |
|
| Cash Flow Statement Financials | |
$-52.41M |
|
$-57.06M |
|
-- |
|
$169.74M |
|
$60.26M |
|
$-109.48M |
|
$4.65M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-52.46M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.68% |
|
-9.68% |
|
-9.15% |
|
-9.68% |
|
$1.34 |
|
$-0.24 |
|
$-0.24 |
|